1. Home
  2. TPG vs BLCO Comparison

TPG vs BLCO Comparison

Compare TPG & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TPG Inc.

TPG

TPG Inc.

HOLD

Current Price

$42.61

Market Cap

7.0B

Sector

Finance

ML Signal

HOLD

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

HOLD

Current Price

$16.16

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TPG
BLCO
Founded
1992
1853
Country
United States
Canada
Employees
1900
N/A
Industry
Investment Managers
Ophthalmic Goods
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0B
5.9B
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
TPG
BLCO
Price
$42.61
$16.16
Analyst Decision
Buy
Buy
Analyst Count
15
11
Target Price
$61.20
$18.45
AVG Volume (30 Days)
2.6M
432.9K
Earning Date
05-01-2026
04-29-2026
Dividend Yield
4.89%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$5,101,000,000.00
Revenue This Year
N/A
$8.65
Revenue Next Year
$19.79
$5.59
P/E Ratio
$106.82
N/A
Revenue Growth
N/A
6.47
52 Week Low
$36.95
$10.99
52 Week High
$70.38
$18.92

Technical Indicators

Market Signals
Indicator
TPG
BLCO
Relative Strength Index (RSI) 46.15 50.08
Support Level $41.43 $14.39
Resistance Level $46.61 $16.61
Average True Range (ATR) 1.82 0.49
MACD -0.13 0.03
Stochastic Oscillator 19.45 78.26

Price Performance

Historical Comparison
TPG
BLCO

About TPG TPG Inc.

TPG Inc is an alternative asset management firm. It invests across five multi-product platforms, namely Capital, Growth, Impact, Real Estate, Market Solutions, and TPG Angelo Gordon. The company invests across a broadly diversified set of strategies, including private equity, impact, credit, real estate, market solutions, innovation, and inclusion.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: